JAMIE S. BARKIN, M.D.; ALBERT M. HARARY, M.D.; COOPER E. SHAMBLEN, PH.D.; KENNETH C. LASSETER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Tablet formations of potassium chloride (KC1) are in wide clinical use, usually in the form of a waxmatrix slow-release tablet. The previously used enteric-coated tablet was withdrawn in 1965 because of numerous reports of intestinal hemorrhage, ulceration, obstruction, and death. The wax-matrix tablets are considered safe, but there have been reports of gastrointestinal ulceration, hemorrhage, obstruction, and perforations (1-3), especially when there was a delay in gut transit. Recently a microencapsulated KC1 preparation has been introduced that does not use a wax matrix. Instead, polymer-coated KC1 crystals are mixed with a dispersing agent that disperses the crystals
BARKIN JS, HARARY AM, SHAMBLEN CE, LASSETER KC. Potassium Chloride and Gastrointestinal Injury. Ann Intern Med. ;98:261–262. doi: 10.7326/0003-4819-98-2-261_2
Download citation file:
Published: Ann Intern Med. 1983;98(2):261-262.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use